Acquired Autoimmune Hemolytic Anemia Global Market Report 2025
상품코드:1760446
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
후천성 자가면역성 용혈성 빈혈 시장 규모는 향후 수 년간 강력한 성장이 전망될 예정입니다. 학술기관의 협력관계 강화, 개별화의료 이용 증가, 고령화 등이 예상됩니다.
자가면역질환의 유병률 증가는 향후 수 년간 후천성 자가면역성 용혈성 빈혈(AIHA) 시장의 성장을 가속할 것으로 예측됩니다. 자가면역 질환은 면역 체계가 신체의 건강한 세포와 조직을 해로운 침입자로 간주하여 잘못 공격할 때 발생합니다. 자가면역 질환의 증가는 주로 면역 체계 조절을 방해하는 환경 요인과 생활 방식의 변화 증가와 관련이 있습니다. 이러한 질환의 유병률이 증가함에 따라 자가면역 질환을 가진 사람들은 면역 체계 조절 장애로 인해 이차성 AIHA에 걸릴 가능성이 높아지기 때문에 후천성 자가면역 용혈성 빈혈의 발생률이 높아집니다. 예를 들어, 2022년 미국의 자가면역 질환 등록 기관 보고서에 따르면, 복합 자가면역 질환으로 진단받은 환자의 비율이 2021년 52%에서 2022년 55%로 증가했습니다.
후천성 자가면역성 용혈성 빈혈 시장의 기업은 치료성적을 개선하고, 부작용을 최소화하고, 환자에 의해 맞춤 치료를 제공하기 위해 인간화 단일클론항체를 포함한 표적요법의 진보에 주목하고 있습니다. 매우 유사하도록 설계된 실험실 수준의 단백질이며, 그 구조의 대부분은 인간이지만, 면역계의 거부 반응을 억제하면서 특정 항원을 표적으로 하는데 도움이 되는 비인간 항체를 약간 포함하고 있습니다. 프랑스에 본사를 두고 있는 건강 관리 기업 Sanofi는 자기 면역성 용혈성 빈혈의 희소형인 한랭 응집소병(CAD)에 대한 최초로 유일한 치료인 Enjaymo(sutimlimab-jome)의 FDA 승인을 취득했습니다. 전적 보체 경로의 C1을 선택적으로 저해하고, 면역계가 건강한 적혈구를 공격하는 것을 막고, CAD 환자에서의 수혈의 필요성을 감소시키고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 후천성 자기면역성 용혈성 빈혈 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 후천성 자가면역성 용혈성 빈혈 시장 : 성장률 분석
세계의 후천성 자가면역성 용혈성 빈혈 시장 실적: 규모와 성장, 2019-2024년
세계의 후천성 자가면역성 용혈성 빈혈 시장 예측 : 규모와 성장, 2024-2029년, 2034년
세계의 후천성 자가면역성 용혈성 빈혈 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 후천성 자가면역성 용혈성 빈혈 시장 : 진단 방법별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
전혈구 수
말초 혈액 도말 샘플
직접 쿰스 검사
간접 쿰스 검사
세계의 후천성 자가면역성 용혈성 빈혈 시장 : 치료 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
코르티코스테로이드
면역억제제
정맥내 면역글로불린
리툭시맙
세계의 후천성 자가면역성 용혈성 빈혈 시장 : 중증도별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
경도
중등도
심도
세계의 후천성 자가면역성 용혈성 빈혈 시장 : 최종 사용자별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
병원
전문 클리닉
연구기관
세계의 후천성 자가면역성 용혈성 빈혈 시장 : 전혈구 계산별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
헤모글로빈치
헤마토크릿(HCT)
망상 적혈구 수
백혈구 수
혈소판 수
세계의 후천성 자가면역성 용혈성 빈혈 시장 : 말초 혈액 도말 샘플별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
구형 적혈구
다색성
분열 세포
망상 적혈구 수 증가
세계의 후천성 자가면역성 용혈성 빈혈 시장 : 직접 쿰스 검사별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
면역글로불린 G 쿰스 검사
면역글로불린 M 쿰스 검사
보체 쿰스 검사
세계의 후천성 자가면역성 용혈성 빈혈 시장 : 간접 쿰스 검사별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
Acquired autoimmune hemolytic anemia (AIHA) is a rare condition where the immune system mistakenly attacks and destroys the body's red blood cells, leading to anemia. It is often triggered by infections, autoimmune diseases, certain cancers, or specific medications, and can develop either suddenly or gradually. This occurs when the body produces antibodies that target its own red blood cells, resulting in hemolysis, or the early destruction of those cells.
The primary diagnostic methods for acquired autoimmune hemolytic anemia include a complete blood count, peripheral blood smear, direct Coombs test, and indirect Coombs test. A complete blood count (CBC) helps detect anemia by identifying low hemoglobin and hematocrit levels, as well as a higher reticulocyte count, which indicates increased red blood cell destruction. Treatment options vary and can include corticosteroids, immunosuppressive drugs, intravenous immunoglobulin, and rituximab. The severity of the disease ranges from mild to moderate to severe. Key end users of these diagnostic and treatment services include hospitals, specialty clinics, and research institutions.
The acquired autoimmune hemolytic anemia market research report is one of a series of new reports from The Business Research Company that provides acquired autoimmune hemolytic anemia market statistics, including the acquired autoimmune hemolytic anemia industry global market size, regional shares, competitors with the acquired autoimmune hemolytic anemia market share, detailed acquired autoimmune hemolytic anemia market segments, market trends, and opportunities, and any further data you may need to thrive in the acquired autoimmune hemolytic anemia industry. This acquired autoimmune hemolytic anemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The acquired autoimmune hemolytic anemia market size has grown strongly in recent years. It will grow from $2.01 billion in 2024 to $2.16 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth observed in the historical period can be attributed to factors such as higher diagnosis rates, an increasing occurrence of secondary AIHA, the expansion of hospital hematology units, support from governments and regulatory bodies, and growing investments in hematology.
The acquired autoimmune hemolytic anemia market size is expected to see strong growth in the next few years. It will grow to $2.88 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period is expected to be driven by the rising incidence of autoimmune diseases, a better understanding of the complement system's role, increased collaboration between biopharma companies and academic institutions, a rise in the use of personalized medicine, and an aging population. Key trends during this period include the adoption of targeted biologic therapies, progress in complement pathway inhibitors, the use of AI and data analytics in disease management, AI-driven clinical trial design, and innovations in orphan drug development.
The growing prevalence of autoimmune disorders is expected to drive the growth of the acquired autoimmune hemolytic anemia (AIHA) market in the coming years. Autoimmune disorders occur when the immune system mistakenly attacks the body's own healthy cells and tissues, viewing them as harmful invaders. This rise in autoimmune disorders is mainly linked to increased environmental factors and lifestyle changes that disrupt immune system regulation. The increasing prevalence of these disorders leads to a higher incidence of acquired autoimmune hemolytic anemia, as individuals with autoimmune conditions are more likely to develop secondary AIHA due to immune system dysregulation. For example, in 2022, the autoimmune registry in the United States reported that the percentage of patients diagnosed with multiple autoimmune conditions increased from 52% in 2021 to 55% in 2022. As such, the growing prevalence of autoimmune disorders will contribute to the expansion of the acquired AIHA market.
Companies in the acquired autoimmune hemolytic anemia market are focusing on advances in targeted therapies, including humanized monoclonal antibodies, to improve treatment outcomes, minimize side effects, and offer more personalized care for patients. Humanized monoclonal antibodies are laboratory-engineered proteins designed to closely resemble human antibodies, with a structure that is mostly human but contains small portions of non-human (often mouse) antibodies to help target specific antigens while reducing immune system rejection. For instance, in February 2022, Sanofi, a healthcare company based in France, received FDA approval for Enjaymo (sutimlimab-jome), the first and only treatment for cold agglutinin disease (CAD), a rare form of autoimmune hemolytic anemia. This treatment selectively inhibits C1s in the classical complement pathway, preventing the immune system from attacking healthy red blood cells and reducing the need for transfusions in CAD patients. Enjaymo specifically targets C1-activated hemolysis while leaving the lectin and alternative complement pathways unaffected.
In September 2023, Bristol Myers Squibb, a biopharmaceutical company based in the U.S., acquired the Asian market rights for obexelimab, a bifunctional monoclonal antibody from Zenas BioPharma, for $50 million. This acquisition aims to expand Bristol Myers Squibb's immunology portfolio and strengthen its position in the Asian market for autoimmune disease treatments. Zenas BioPharma is a U.S.-based clinical-stage biopharmaceutical company that focuses on developing immunology therapies for autoimmune diseases, including acquired autoimmune hemolytic anemia.
Major players in the acquired autoimmune hemolytic anemia market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi SA, Novartis AG, Amgen Inc., Incyte Corporation, Alexion Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Annexon Inc., Rigel Pharmaceuticals Inc., Nanjing IASO Biotherapeutics Co. Ltd., Apellis Pharmaceuticals Inc., Momenta Pharmaceuticals Inc., Zenas BioPharma Inc., Immunovant Sciences GmbH, Alpine Immune Sciences Inc., Agios Pharmaceuticals Inc., Rakshit Drugs Private Limited, Aarti Pharmalabs Ltd.
North America was the largest region in the acquired autoimmune hemolytic anemia market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in acquired autoimmune hemolytic anemia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the acquired autoimmune hemolytic anemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The acquired autoimmune hemolytic anemia market consists of revenues earned by entities by providing services such as diagnosis services, treatment and medication services, clinical trials, and research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The acquired autoimmune hemolytic anemia market also includes sales of prednisone, and methylprednisolone. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Acquired Autoimmune Hemolytic Anemia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on acquired autoimmune hemolytic anemia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for acquired autoimmune hemolytic anemia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acquired autoimmune hemolytic anemia market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Diagnosis Method: Complete Blood Count; Peripheral Blood Smear; Direct Coombs Test; Indirect Coombs Test
2) By Treatment Type: Corticosteroids; Immunosuppressive Agents; Intravenous Immunoglobulin; Rituximab
3) By Severity: Mild; Moderate; Severe
4) By End User: Hospitals; Specialty Clinics; Research Institutions
Subsegment:
1) By Complete Blood Count: Hemoglobin Level; Hematocrit (HCT); Reticulocyte Count; White Blood Cell Count; Platelet Count
3. Acquired Autoimmune Hemolytic Anemia Market Trends And Strategies
4. Acquired Autoimmune Hemolytic Anemia Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Acquired Autoimmune Hemolytic Anemia Growth Analysis And Strategic Analysis Framework
5.1. Global Acquired Autoimmune Hemolytic Anemia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Acquired Autoimmune Hemolytic Anemia Market Growth Rate Analysis
5.4. Global Acquired Autoimmune Hemolytic Anemia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Acquired Autoimmune Hemolytic Anemia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Acquired Autoimmune Hemolytic Anemia Total Addressable Market (TAM)
6.1. Global Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Complete Blood Count
Peripheral Blood Smear
Direct Coombs Test
Indirect Coombs Test
6.2. Global Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Corticosteroids
Immunosuppressive Agents
Intravenous Immunoglobulin
Rituximab
6.3. Global Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Mild
Moderate
Severe
6.4. Global Acquired Autoimmune Hemolytic Anemia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Research Institutions
6.5. Global Acquired Autoimmune Hemolytic Anemia Market, Sub-Segmentation Of Complete Blood Count, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hemoglobin Level
Hematocrit (HCT)
Reticulocyte Count
White Blood Cell Count
Platelet Count
6.6. Global Acquired Autoimmune Hemolytic Anemia Market, Sub-Segmentation Of Peripheral Blood Smear, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Spherocytes
Polychromasia
Schistocytes
Increased Reticulocyte Count
6.7. Global Acquired Autoimmune Hemolytic Anemia Market, Sub-Segmentation Of Direct Coombs Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immunoglobulin G Coombs Test
Immunoglobulin M Coombs Test
Complement Coombs Test
6.8. Global Acquired Autoimmune Hemolytic Anemia Market, Sub-Segmentation Of Indirect Coombs Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Screening For Alloantibodies
Detection Of Sensitizing Antibodies
Crossmatch Testing
7. Acquired Autoimmune Hemolytic Anemia Market Regional And Country Analysis
7.1. Global Acquired Autoimmune Hemolytic Anemia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Acquired Autoimmune Hemolytic Anemia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Acquired Autoimmune Hemolytic Anemia Market
9.1. China Acquired Autoimmune Hemolytic Anemia Market Overview
9.2. China Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Acquired Autoimmune Hemolytic Anemia Market
10.1. India Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Acquired Autoimmune Hemolytic Anemia Market
11.1. Japan Acquired Autoimmune Hemolytic Anemia Market Overview
11.2. Japan Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Acquired Autoimmune Hemolytic Anemia Market
12.1. Australia Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Acquired Autoimmune Hemolytic Anemia Market
13.1. Indonesia Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Acquired Autoimmune Hemolytic Anemia Market
14.1. South Korea Acquired Autoimmune Hemolytic Anemia Market Overview
14.2. South Korea Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Acquired Autoimmune Hemolytic Anemia Market
15.1. Western Europe Acquired Autoimmune Hemolytic Anemia Market Overview
15.2. Western Europe Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Acquired Autoimmune Hemolytic Anemia Market
16.1. UK Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.1. Spain Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Acquired Autoimmune Hemolytic Anemia Market
21.1. Eastern Europe Acquired Autoimmune Hemolytic Anemia Market Overview
21.2. Eastern Europe Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Acquired Autoimmune Hemolytic Anemia Market
22.1. Russia Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Acquired Autoimmune Hemolytic Anemia Market
23.1. North America Acquired Autoimmune Hemolytic Anemia Market Overview
23.2. North America Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Acquired Autoimmune Hemolytic Anemia Market
24.1. USA Acquired Autoimmune Hemolytic Anemia Market Overview
24.2. USA Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Acquired Autoimmune Hemolytic Anemia Market
26.1. South America Acquired Autoimmune Hemolytic Anemia Market Overview
26.2. South America Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Acquired Autoimmune Hemolytic Anemia Market
27.1. Brazil Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Acquired Autoimmune Hemolytic Anemia Market
28.1. Middle East Acquired Autoimmune Hemolytic Anemia Market Overview
28.2. Middle East Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Acquired Autoimmune Hemolytic Anemia Market
29.1. Africa Acquired Autoimmune Hemolytic Anemia Market Overview
29.2. Africa Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Acquired Autoimmune Hemolytic Anemia Market Competitive Landscape And Company Profiles
